R
Rajendra A. Badwe
Researcher at Tata Memorial Hospital
Publications - 168
Citations - 7360
Rajendra A. Badwe is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 34, co-authored 118 publications receiving 5878 citations. Previous affiliations of Rajendra A. Badwe include Homi Bhabha National Institute.
Papers
More filters
Journal ArticleDOI
Suicide mortality in India: a nationally representative survey
Rajesh Dikshit,Prakash C. Gupta,Chinthanie Ramasundarahettige,Vendhan Gajalakshmi,Lukasz Aleksandrowicz,Rajendra A. Badwe,Rajesh Kumar,Sandip Roy,Wilson Suraweera,Freddie Bray,Mohandas K. Mallath,Poonam Singh,Dhirendra N Sinha,Arun S. Shet,Hellen Gelband,Prabhat Jha +15 more
TL;DR: This work aimed to quantify suicide mortality in India in 2010 by applying the age-specific and sex-specific proportion of suicide deaths in this survey to the 2010 UN estimates of absolute numbers of deaths in India.
Journal ArticleDOI
Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer
Abstr Act,Richa Vaish,Neeti Kapre,Mitali Dandekar,Sudeep Gupta,Rohini Hawaldar,Jai Prakash Agarwal,Gouri Pantvaidya,Devendra Chaukar,Anuja Deshmukh,Shubhada Kane,Supreeta Arya,Sarbani Ghosh-Laskar,Pankaj Chaturvedi,Prathamesh S. Pai,Sudhir Nair,Deepa Nair,Rajendra A. Badwe +17 more
TL;DR: Elective node dissection was superior in most subgroups without significant interactions and among patients with early-stage oral squamous-cell cancer, elective neck dissection resulted in higher rates of overall and disease-free survival than did therapeutic neck dissections.
Journal ArticleDOI
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Harold J. Burstein,Yan Sun,Luc Dirix,Zefei Jiang,Robert Paridaens,Antoinette R. Tan,Ahmad Awada,Anantbhushan Ranade,Shunchang Jiao,Gary G. Schwartz,Richat Abbas,Christine Powell,Kathleen Turnbull,Jennifer Vermette,Charles Zacharchuk,Rajendra A. Badwe +15 more
TL;DR: Oral neratinib showed substantial clinical activity and was reasonably well tolerated among both heavily pretreated and trastuzumab-naïve patients who had advanced, ErbB2-positive breast cancer.
Journal ArticleDOI
Challenges to effective cancer control in China, India, and Russia
Paul E. Goss,Kathrin Strasser-Weippl,Brittany L. Lee-Bychkovsky,Brittany L. Lee-Bychkovsky,Lei Fan,Lei Fan,Junjie Li,Junjie Li,Yanin Chavarri-Guerra,Pedro E.R. Liedke,C S Pramesh,Tanja Badovinac-Crnjevic,Yuri Sheikine,Yuri Sheikine,Zhu Chen,You-Lin Qiao,Z Shao,Yi-Long Wu,Daiming Fan,Louis W.C. Chow,Jun Wang,Qiong Zhang,Shiying Yu,Gordon C Shen,Gordon C Shen,Jie He,Arnie Purushotham,Richard Sullivan,Rajendra A. Badwe,Shripad Banavali,Reena Nair,Lalit Kumar,Purvish M. Parikh,Somasundarum Subramanian,Pankaj Chaturvedi,Subramania Iyer,Surendra S Shastri,Raghunadhrao Digumarti,Enrique Soto-Perez-de-Celis,Dauren Adilbay,Vladimir Semiglazov,Sergey Orlov,Dilyara Kaidarova,Ilya Tsimafeyeu,Sergei Tatishchev,Kirill D. Danishevskiy,Marc Hurlbert,Caroline Vail,Jessica St. Louis,A. Chan +49 more
TL;DR: The overall state of health and cancer control in each country is described and additional specific issues for consideration are described: for China, access to care, contamination of the environment, and cancer fatalism and traditional medicine; for India, affordability of care, provision of adequate health personnel, and sociocultural barriers to cancer control.
Journal ArticleDOI
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
Rajendra A. Badwe,Rohini Hawaldar,Nita S. Nair,Rucha Vishal Kaushik,Vani Parmar,Shabina Siddique,Ashwini Budrukkar,Indraneel Mittra,Sudeep Gupta +8 more
TL;DR: In this paper, the authors compared the effect of locoregional treatment with no treatment on outcome in women with metastatic breast cancer at initial presentation, and found that there is no evidence to suggest that the treatment of the primary tumor affects overall survival in patients who have responded to front-line chemotherapy.